Probucol inhibits ABCA1-mediated cellular lipid efflux

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 12, 2004, Pages 2345-2350

  Favari, Elda ^a   Zanotti, Ilaria ^a   Zimetti, Francesca ^a   Ronda, Nicoletta ^a   Bernini, Franco ^a   Rothblat, George H ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

ABCA1; Fibroblasts; Lipid efflux; Macrophages; Probucol

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; PROBUCOL; PROTEIN ACBA1; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOTINYLATION; CELL MEMBRANE; CELL SURFACE; CELL TRANSPORT; CELLULAR DISTRIBUTION; CHOLESTEROL TRANSPORT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPID TRANSPORT; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROBLAST;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; FIBROBLASTS; HUMANS; LIPID METABOLISM; LIVER NEOPLASMS, EXPERIMENTAL; MACROPHAGES; PROBUCOL;

EID: 10644257633     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000148706.15947.8a     Document Type: Article

References (31)

1. Davignon J. Medical management of hyperlipidemia and the role of probucol. Am J Cardiol. 1986;57:22H-28H.
2. Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B. Effects of probucol on xanthoma regression in familial hypercholesterolemia. Am J Cardiol. 1986;57:29H-36H.
3. Franceschini G, Werba JP, Calabresi L. Drug control of reverse cholesterol transport. Pharmacol Ther. 1994;6:289-324.
4. Braun A, Zhang S, Miettinen HE, Ebrahim S, Holm TM, Vasile E, Post MJ, Yoerger DM, Picard MH, Krieger JL, Andrews NC, Simons M, Krieger M. Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. Proc Natl Acad Sci U S A. 2003;100:7283-7288.
5. Yamamoto A, Hara H, Takaku F, Wakasugi JI, Tomikawa M. Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. Am J Cardiol. 1988;62:31B-36B.
6. Goldberg RB, Mendez A. Probucol enhances cholesterol efflux from cultured human skin fibroblasts. Am J Cardiol. 1988;62:57B-59B.
7. Zambon S, Brazg R, Aviram M, Oram JF, Bierman EL. The effect of probucol on HDL-mediated sterol translocation and efflux from cells. Atherosclerosis. 1992;94:51-60.
8. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH. Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vascular Biol. 2003;23:712-719.
9. Williams DL, Connelly MA, Temel RE, Swanakar S, Phillips MC, de la Llera-Moya M, Rothblat GH. Scavenger receptor BI and cholesterol trafficking. Curr Opin Lipidol. 1999;10:329-339.
10. Oram JF, Vaughan AM. ABC1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins. Curr Opin Lipidol. 2000;11:253-260.
11. Wang N, Tall AR. Regulation and mechanisms of ATP-binding cassette transporter AI-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003;23:1178-1184.
12. Tsujita M, Yokoyama S. Selective inhibition of free apolipoprotein- mediated cellular lipid efflux by probucol. Biochemistry. 1996;35:13011-13020.
13. Sakr SW, Williams DL, Stoudt GW, Phillips MC, Rothblat GH. Induction of cellular cholesterol efflux to lipid-free apolipoprotein A-I by cAMP. Biochim Biophys Acta. 1999;1438:85-98.
14. Tsujita M, Tomimoto S, Okumura-Noji K, Okazaki M, Yokoyama S. Apolipoprotein-mediated cellular cholesterol/phospholipid efflux and plasma high density lipoprotein level in mice. Biochim Biophys Acta. 2000;1485:199-213.
15. Takemura T, Sakai M, Matsuda H, Matsumura T, Biwa T, Anami Y, Nishikawa T, Sasahara T, Shichiri M. Effects of probucol on cholesterol metabolism in mouse peritoneal macrophages: inhibition of HDL-mediated cholesterol efflux. Atherosclerosis. 2000;152:347-357.
16. Kellner-Weibel G, Luke SJ, Rothblat GH. Cytotoxic cellular cholesterol is selectively removed by apoA-I via ABCA1. Atherosclerosis. 2003;171:235-243.
17. Bernini F, Calabresi L, Bonfadini G, Franceschini G. The molecular structure of apolipoprotein A-II modulates the capacity of HDL to promote cell cholesterol efflux. Biochim Biophys Acta. 1996;1299:103-109.
18. Franceschini G, Vecchio G, Gianfranceschi G, Magani G, Sirtori CR. Apolipoprotein AIMilano. Accelerated binding and dissociation from lipids of a human apolipoprotein variant. J Biol Chem. 1985;260:16321-16325.
19. Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, Bernini F, Kovanen PT. Depletion of PREbeta-HDL by human chymase impairs ATP-binding cassette transporter A1- but not SR-BI-mediated lipid efflux to HDL. J Biol Chem. 2003;279:9930-9936.
20. Yancey PG, Bielicki JK, Johnson WJ, Lund-Katz S, Palgunachari LM, Anantharamaiah GM, Segrest JP, Phillips MC, Rothblat GH. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry. 1995;34:7955-7965.
21. Kellner-Weibel G, de la Llera-Moya M, Connelly MA, Stoudt G, Christian AE, Haynes MP, Williams DL, Rothblat GH. Expression of scavenger receptor BI in COS-7 cells alters cholesterol content and distribution. Biochemistry. 2000;39:221-229.
22. Ji Y, Jian B, Wang N, Sun Y, de la Llera Moya M, Phillips MC, Rothblat GH, Swaney JB, Tall AR. Scavenger receptor B1 promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem. 1997;272:20982-20985.
23. Arakawa R, Yokoyama S. Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation. J Biol Chem. 2002;277:22426-22429.
24. Neufeld EB, Remaley AT, Demosky SJ, Stonik JA, Cooney AM, Comly M, Dwyer NK, Zhang M, Santamarina-Fojo S, Brewer HB Jr, Blanchette-Mackie EJ. Cellular localization and trafficking of the human ABCA1 transporter. J Biol Chem. 2001;276:27584-27590.
25. Vaughan AM, Oram JF. ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res. 2003;44:1373-1380.
26. Bernini F, Bellosta S, Corsini A, Maggi FM, Fumagalli R, Catalano AL. Cholesterol stimulation of HDL binding to human endothelial cells EAhy 926 and skin fibroblasts: evidence for a mechanism independent of cellular metabolism. Biochim Biophys Acta. 1991;1083:94-100.
27. Wu CA, Tsujita M, Hayashi M, Yokoyama S. Probucol inactivates ABCA1 in the plasma membrane with respect to its mediation of apolipoprotein binding and high density lipoprotein assembly and to its proteolytic degradation. J Biol Chem. 2004;279:30168-30174.
28. Beynen AC. Mode of hypocholesterolemic action of probucol in animals and man. Artery. 1987;14:113-126.
29. Chiesa G, Michelagnoli S, Cassinotti M, Gianfranceschi G, Werba JP, Pazzucconi F, Sirtori CR, Franceschini G. Mechanisms of high-density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activities. Metabolism. 1993;42:229-235.
30. Rinninger F, Wang N, Ramakrishnan R, Jiang XC, Tall AR. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol. 1999;19:1325-1332.
31. de la Llera-Moya M, Connelly MA, Drazul D, Klein SM, Favari E, Yancey PG, Williams DL, Rothblat GH. Scavenger receptor, class B, type I (SR-BI) affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. J Lip Res. 2001;42:1969-1978.